Evidence map›Paper›PMID 33544240›Full record

Trial reportThe international journal of cardiovascular imaging2021

The effect of spironolactone on diastolic function in haemodialysis patients.

T Hauser, V Dornberger, U Malzahn, S J Grebe, D Liu, S Störk, M Nauck, N Friedrich, M Dörr, C Wanner and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of cardiovascular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

T Hauser *Division of Nephrology, Department of Medicine I, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany. E_Hauser_T@ukw.de.ORCID http://orcid.org/0000-0001-7097-2815
V Dornberger *Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
U MalzahnClinical Trial Centre, University Hospital Würzburg, Würzburg, Germany.
S J GrebeDepartment of Paediatrics, University Hospital of Erlangen, Erlangen, Germany.
D LiuDivision of Nephrology, Department of Medicine I, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany.
S StörkDivision of Nephrology, Department of Medicine I, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany.
M NauckInstitute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
N FriedrichInstitute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
M DörrDepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
C WannerDivision of Nephrology, Department of Medicine I, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany.
V KraneDivision of Nephrology, Department of Medicine I, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany.
F HammerDepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
MiREnDa Study Group
Collaborating investigators (sites)
Universitätsklinikum Würzburg · DEUniversitätsmedizin Greifswald · DEUniversitätsklinikum Erlangen · DE

Funding

Bundesministerium für Bildung und Forschung 01KG1202
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in patients on maintenance haemodialysis (HD) and lacks effective treatment. We investigated the effect of spironolactone on cardiac structure and function with a specific focus on diastolic function parameters. The MiREnDa trial examined the effect of 50 mg spironolactone once daily versus placebo on left ventricular mass index (LVMi) among 97 HD patients during 40 weeks of treatment. In this echocardiographic substudy, diastolic function was assessed using predefined structural and functional parameters including E/e'. Changes in the frequency of HFpEF were analysed using the comprehensive 'HFA-PEFF score'. Complete echocardiographic assessment was available in 65 individuals (59.5 ± 13.0 years, 21.5% female) with preserved left ventricular ejection fraction (LVEF > 50%). At baseline, mean E/e' was 15.2 ± 7.8 and 37 (56.9%) patients fulfilled the criteria of HFpEF according to the HFA-PEFF score. There was no significant difference in mean change of E/e' between the spironolactone group and the placebo group (+ 0.93 ± 5.39 vs. + 1.52 ± 5.94, p = 0.68) or in mean change of left atrial volume index (LAVi) (1.9 ± 12.3 ml/m

Indexed as

Heart FailureSpironolactoneAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsRenal DialysisStroke VolumeVentricular Function, LeftSpironolactoneDiastolic functionEchocardiographyE/e’HaemodialysisHFpEFSpironolactone

Identifiers

PMID33544240
PMCPMC8255262
OpenAlexW3126621039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.